BR112022018945A2 - Tecnologias para prevenir ou tratar infecções - Google Patents
Tecnologias para prevenir ou tratar infecçõesInfo
- Publication number
- BR112022018945A2 BR112022018945A2 BR112022018945A BR112022018945A BR112022018945A2 BR 112022018945 A2 BR112022018945 A2 BR 112022018945A2 BR 112022018945 A BR112022018945 A BR 112022018945A BR 112022018945 A BR112022018945 A BR 112022018945A BR 112022018945 A2 BR112022018945 A2 BR 112022018945A2
- Authority
- BR
- Brazil
- Prior art keywords
- technologies
- prevent
- treat infections
- present disclosure
- disclosure provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994779P | 2020-03-25 | 2020-03-25 | |
| US202063001455P | 2020-03-29 | 2020-03-29 | |
| US202063055860P | 2020-07-23 | 2020-07-23 | |
| PCT/US2021/024186 WO2021195401A1 (en) | 2020-03-25 | 2021-03-25 | Technologies for preventing or treating infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018945A2 true BR112022018945A2 (pt) | 2022-12-13 |
Family
ID=77890439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018945A BR112022018945A2 (pt) | 2020-03-25 | 2021-03-25 | Tecnologias para prevenir ou tratar infecções |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230330240A1 (https=) |
| EP (1) | EP4125893A4 (https=) |
| JP (1) | JP2023520188A (https=) |
| KR (1) | KR20220158762A (https=) |
| CN (1) | CN115697415A (https=) |
| AU (1) | AU2021244228A1 (https=) |
| BR (1) | BR112022018945A2 (https=) |
| CA (1) | CA3176256A1 (https=) |
| IL (1) | IL296725A (https=) |
| MX (1) | MX2022011692A (https=) |
| PH (1) | PH12022552499A1 (https=) |
| WO (1) | WO2021195401A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022159372A1 (en) | 2021-01-22 | 2022-07-28 | Decoy Therapeutics, Inc. | Methods and compositions for treating infections |
| WO2023150375A2 (en) * | 2022-02-07 | 2023-08-10 | Decoy Therapeutics Inc. | Methods and compositions for treating covid infections |
| CN116440285A (zh) * | 2023-04-19 | 2023-07-18 | 山西锦波生物医药股份有限公司 | 冠状病毒多肽类融合抑制剂的长效化的方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3069986A1 (en) * | 2017-07-26 | 2019-01-31 | Kleo Pharmaceuticals, Inc. | Universal abt compounds and uses thereof |
-
2021
- 2021-03-25 AU AU2021244228A patent/AU2021244228A1/en not_active Abandoned
- 2021-03-25 US US17/912,563 patent/US20230330240A1/en active Pending
- 2021-03-25 KR KR1020227036445A patent/KR20220158762A/ko active Pending
- 2021-03-25 MX MX2022011692A patent/MX2022011692A/es unknown
- 2021-03-25 IL IL296725A patent/IL296725A/en unknown
- 2021-03-25 EP EP21775066.0A patent/EP4125893A4/en active Pending
- 2021-03-25 WO PCT/US2021/024186 patent/WO2021195401A1/en not_active Ceased
- 2021-03-25 CN CN202180035832.5A patent/CN115697415A/zh active Pending
- 2021-03-25 JP JP2022557130A patent/JP2023520188A/ja active Pending
- 2021-03-25 BR BR112022018945A patent/BR112022018945A2/pt unknown
- 2021-03-25 CA CA3176256A patent/CA3176256A1/en active Pending
- 2021-03-25 PH PH1/2022/552499A patent/PH12022552499A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230330240A1 (en) | 2023-10-19 |
| MX2022011692A (es) | 2023-02-09 |
| JP2023520188A (ja) | 2023-05-16 |
| CA3176256A1 (en) | 2021-09-30 |
| EP4125893A4 (en) | 2024-10-16 |
| EP4125893A1 (en) | 2023-02-08 |
| KR20220158762A (ko) | 2022-12-01 |
| PH12022552499A1 (en) | 2024-03-25 |
| IL296725A (en) | 2022-11-01 |
| AU2021244228A1 (en) | 2022-11-17 |
| WO2021195401A1 (en) | 2021-09-30 |
| CN115697415A (zh) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022018945A2 (pt) | Tecnologias para prevenir ou tratar infecções | |
| CY1125071T1 (el) | Θεραπεια του συνδρομου ευθραυστου χ με κανναβιδιολη | |
| CL2023003068A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
| MX2021014742A (es) | Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus. | |
| BR112020012647A8 (pt) | Anticorpos anti-tígitos e seu uso como agentes terapêu-ticos e diagnósticos | |
| MX2021013974A (es) | Metodos, sistemas y dispositivos de seleccion de pacientes tl1a. | |
| CO2018003168A2 (es) | Moduladores de la expresión de kras | |
| CR20240363A (es) | Compuestos y métodos para el tratamiento de infecciones virales. | |
| BR112022007677A2 (pt) | L-asparaginase recombinante | |
| BR112019004496A2 (pt) | estabilizantes de mastócitos para tratamento de hipercitocinemia e infecção viral | |
| ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
| BR112021022951A2 (pt) | Composições e métodos para o tratamento de doenças mediadas por atpase | |
| BR112019009256A2 (pt) | métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo | |
| TW201613575A (en) | Treatment of polybacterial infections | |
| BR112015029367A2 (pt) | terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas | |
| MX2021002719A (es) | Cannabinoides para el tratamiento de infecciones grampositivas incluidas cepas bacterianas resistentes a antibióticos. | |
| BR112021025421A2 (pt) | Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos | |
| MX2016016139A (es) | Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5. | |
| MX2017014257A (es) | Metodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con celulas t. | |
| MX2021015448A (es) | Células linfocíticas activadas y métodos para usarlas para tratar cáncer y afecciones infecciosas. | |
| BR112018067967A2 (pt) | tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante | |
| BR112022008164A2 (pt) | Terapia de combinação para tratar câncer cerebral | |
| BR112022002025A2 (pt) | Composições e métodos para tratar águas residuais | |
| BR112021021787A2 (pt) | Terapias de combinação | |
| MX2021000601A (es) | Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |